Insider · CIK 0001682019

Kulkarni Samarth

Reports to the SEC for 5 companies · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001682019

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-14	CRSPCRISPR Therapeutics AGS Sale	Director, Chief Executive Officer	SSale	−4,098 sh	$49.26	−$202K	259,736
2026-10-13	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+8,333 sh	—	—	263,834
2026-10-13	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−8,333 sh	—	—	0
2026-06-26	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2026-06-24	Centessa Pharmaceuticals plcShare Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−208K sh	—	—	0
2026-06-24	Centessa Pharmaceuticals plcShare Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−48K sh	—	—	0
2026-06-24	Centessa Pharmaceuticals plcShare Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−48K sh	—	—	0
2026-06-24	Centessa Pharmaceuticals plcShare Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−48K sh	—	—	0
2026-06-24	Centessa Pharmaceuticals plcShare Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−40K sh	—	—	0
2026-06-02	ORKAOruka Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+9,136 sh	—	—	9,136
2026-03-23	CRSPCRISPR Therapeutics AGS Sale	Director, Chief Executive Officer	SSale	−10K sh	$46.78	−$469K	255,501
2026-03-20	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+19.7K sh	—	—	265,521
2026-03-20	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	Director, Chief Executive Officer	AAward	+81.9K sh	—	—	81,875
2026-03-20	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−19.7K sh	—	—	39,375
2026-03-20	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+114K sh	—	—	114,249
2026-03-16	CRSPCRISPR Therapeutics AGS Sale	Director, Chief Executive Officer	SSale	−10.3K sh	$48.26	−$499K	245,834
2026-03-14	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−20.6K sh	—	—	61,875
2026-03-14	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+20.6K sh	—	—	256,183
2026-03-11	CRSPCRISPR Therapeutics AGS Sale	Director, Chief Executive Officer	SSale	−9,798 sh	$52.80	−$517K	235,558
2026-03-10	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−19.3K sh	—	—	19,250
2026-03-10	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+19.3K sh	—	—	245,356
2026-02-19	CRSPCRISPR Therapeutics AGS Sale	Director, Chief Executive Officer	SSale	−6,967 sh	$52.58	−$366K	226,106
2026-02-18	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−13.3K sh	—	—	0
2026-02-18	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+13.3K sh	—	—	233,073
2026-01-22	CRSPCRISPR Therapeutics AGS Sale	Director, Chief Executive Officer	SSale	−60K sh	$60.23	−$3.61M	134,201
2026-01-20	CRSPCRISPR Therapeutics AGS Sale	Director, Chief Executive Officer	SSale	−8,567 sh	$52.10	−$446K	194,201
2026-01-20	CRSPCRISPR Therapeutics AGS Sale	Director, Chief Executive Officer	SSale	−21.4K sh	$51.61	−$1.11M	202,768
2025-12-18	CRSPCRISPR Therapeutics AGG Gift	Director, Chief Executive Officer	GGift	−30K sh	—	—	224,201
2025-10-17	CRSPCRISPR Therapeutics AGS Sale	Director, Chief Executive Officer	SSale	−50.9K sh	$67.91	−$3.46M	254,201
2025-10-16	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+100K sh	—	—	305,096
2025-10-16	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−100K sh	—	—	300,000
2025-10-14	CRSPCRISPR Therapeutics AGS Sale	Director, Chief Executive Officer	SSale	−4,242 sh	$66.60	−$283K	205,096
2025-10-13	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−8,334 sh	—	—	8,333
2025-10-13	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+8,334 sh	—	—	209,338
2025-10-03	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+49.5K sh	—	—	49,500
2025-09-17	CRSPCRISPR Therapeutics AGG Gift	Director, Chief Executive Officer	GGift	−6,000 sh	—	—	201,004
2025-08-18	CRSPCRISPR Therapeutics AGS Sale	Director, Chief Executive Officer	SSale	−13.1K sh	$58.15	−$761K	207,004
2025-08-16	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+25K sh	—	—	220,085
2025-08-16	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−25K sh	—	—	0
2025-06-20	Centessa Pharmaceuticals plcShare Option (right to buy)A Award	Director	AAward	+40K sh	—	—	40,000
2025-06-12	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+30.6K sh	—	—	30,550
2025-06-02	ORKAOruka Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+17.5K sh	—	—	17,500
2025-03-21	CRSPCRISPR Therapeutics AGS Sale	Director, Chief Executive Officer	SSale	−10K sh	$41.23	−$414K	195,085
2025-03-20	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−19.7K sh	—	—	59,062
2025-03-20	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+19.7K sh	—	—	205,116
2025-03-14	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+110K sh	—	—	110,000
2025-03-14	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	Director, Chief Executive Officer	AAward	+82.5K sh	—	—	82,500
2025-03-12	CRSPCRISPR Therapeutics AGS Sale	Director, Chief Executive Officer	SSale	−4,462 sh	$43.32	−$193K	185,428
2025-03-11	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−9,000 sh	—	—	0
2025-03-11	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+9,000 sh	—	—	189,890

Recent filings

Accepted (ET)
Oct 15 17:354
Kulkarni Samarth0001193125-26-423056
SEC(opens sec.gov)
Jun 294
Kulkarni Samarth0001682019-26-000002
SEC(opens sec.gov)
Jun 244
Kulkarni Samarth0001470831-26-000608
SEC(opens sec.gov)
Jun 34
Kulkarni Samarth0000907654-26-000051
SEC(opens sec.gov)
Mar 244
Kulkarni Samarth0001193125-26-122272
SEC(opens sec.gov)
Mar 174
Kulkarni Samarth0001193125-26-111278
SEC(opens sec.gov)
Mar 124
Kulkarni Samarth0001193125-26-104480
SEC(opens sec.gov)

Companies

Address

C/O CRISPR THERAPEUTICS 105 WEST FIRST STREET

BOSTON, MA, 02127